The finalization of the ICH E6(R3) Good Clinical Practice (GCP) guideline represents the most significant evolution in clinical trial management in a decade. For sponsors and CROs, this is not a minor update to be filed away; it is a mandatory shift to a new operating system. One that demands a move from a reactive to a proactive philosophy of quality.
For years, the industry has relied on an illusion of quality, anchored by labor-intensive, reactive processes like 100% Source Data Verification (SDV). This approach focuses on catching mistakes long after they’ve occurred, leading to a cycle of data queries, costly rework, and preventable delays.
The new ICH E6(R3) mandate flips this model on its head. The core principle is Quality by Design (QbD), a framework built on:
- Proactively identifying what is critical to quality (CTQ) for patient safety and data integrity before a trial begins.
- Assessing the risks to those critical factors.
- Implementing a risk-based monitoring (RBQM) strategy that uses technology and Key Risk Indicators (KRIs) to focus resources on what truly matters.
Compliance with this new guideline requires more than just a new SOP; it requires a purpose-built quality system. It’s here that the choice of a CRO partner becomes paramount.
Accelsiors’ QualityDRIVE™ is our proprietary methodology designed to operationalize the principles of ICH E6(R3). It provides the framework, tools, and technology to move beyond the old, reactive path and embrace a proactive system that prevents errors, ensures data integrity, and delivers inspection-ready results.
The visual below shows the stark difference between these two approaches. (Embed the “QualityDRIVE™ Advantage” Infographic Here)
Discover how this proactive quality system integrates into a complete global regulatory strategy in our comprehensive guide.
Download our new White Paper,
“Mastering the Regulatory Gauntlet”, for the complete framework.